Analysis of Pharmaceutical Raw Materials Compliant with ICH Q3D Guideline Using ICP-MS with Collision Mode

Applications | 2025 | ShimadzuInstrumentation
ICP/MS
Industries
Pharma & Biopharma
Manufacturer
Shimadzu

Significance of the Topic


Elemental impurities in pharmaceutical products pose significant health risks and must be controlled to comply with international safety standards. The ICH Q3D guideline defines Permitted Daily Exposures (PDEs) for 24 toxicologically relevant elements. Reliable determination of trace metals in raw materials is essential for quality assurance, regulatory compliance, and patient safety.

Study Objectives and Overview


This study demonstrates the use of the Shimadzu ICPMS-2040 with an organic solvent system to quantify 24 elements specified in ICH Q3D in three pharmaceutical raw materials (aspirin, salicylic acid, and ibuprofen) prepared in ethanol. Key performance parameters—accuracy, precision, detection limits, and specificity—were evaluated against pharmacopeial requirements (USP, EP).

Methodology and Sample Preparation


Sample preparation steps:
  1. Dissolve 0.1 g of each raw material in 10 mL eluent (500 mL ethanol with 5 mL HNO₃ and 2.5 mL HCl) to achieve a 100× dilution factor.
  2. Prepare calibration standards at 0.5J, 1.0J, and 1.5J concentrations based on PDEs for each element.
  3. Add internal standards (Be, Bi, Ga, Y at 0.2 mg/L) online during analysis.
  4. Perform spike recoveries at 50 %, 100 %, and 150 % of target concentrations for accuracy and precision assessments.

Used Instrumentation


Instrumentation configuration:
  • ICP-MS Model: Shimadzu ICPMS-2040 with organic solvent torch.
  • Nebulizer: DC04; chamber cooled to –5 °C; platinum sampling cone; nickel skimmer cone.
  • Gas flows: plasma 20 L/min, auxiliary 0.5 L/min, carrier 0.55 L/min, mix gas 0.35 L/min; He collision gas at 7 mL/min.
  • RF power: 1.60 kW; sampling depth: 8 mm; peristaltic pump speed: 20 rpm.

Main Results and Discussion


Detection Limits and Calibration:
  • Instrument detection limits ranged from 0.0007 µg/L (Tl) to 0.9 µg/L (Se).
  • Linear calibration curves met criteria across the 0.5J–1.5J range.
Accuracy and Precision:
  • Spike recoveries for all elements fell between 94 % and 111 %, exceeding the 70 %–150 % acceptance range.
  • Repeatability (RSD) values were below 3.8 %, well under the 20 % threshold.
  • Limits of quantitation were confirmed by accurate results at 50 % target concentrations.
Specificity and Interference Correction:
  • MoO interference on Cd was effectively eliminated by combining He collision gas with interelement correction, delivering non-detectable false contributions.

Benefits and Practical Applications


This validated method enables simultaneous, high-sensitivity measurement of 24 elemental impurities in ethanol-based pharmaceutical samples. It simplifies sample preparation, accelerates routine QC testing, and supports adherence to ICH Q3D guidelines. The online internal standard addition reduces manual handling and improves analytical throughput.

Future Trends and Potential Applications


Emerging directions include automation of sample digestion, expansion to complex dosage forms, integration with hyphenated separation techniques for compound-specific impurity profiling, and real-time on-line monitoring in manufacturing processes. Advances in collision/reaction cell technology and data processing algorithms will further enhance interference removal and sensitivity.

Conclusion


The Shimadzu ICPMS-2040 organic solvent system demonstrates robust performance for quantitative analysis of ICH Q3D elements in pharmaceutical raw materials. Validation results confirm compliance with pharmacopeial accuracy, precision, specificity, and detection limit requirements, affirming its suitability for routine impurity testing.

References


  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for Elemental Impurities Q3D, 2015.
  2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q3D(R2) Guideline for Elemental Impurities, 2023.
  3. USP General Chapter <232> Elemental Impurities—Limits.
  4. USP General Chapter <233> Elemental Impurities—Procedures.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Analysis of Pharmaceutical Raw Materials Compliant with ICH Q3D Guideline Using ICP-MS with Collision/Reaction Mode
Analysis of Artificial Tear Eye Drops For Elemental Impurities
Accurate and Robust Measurement of Elemental Impurities in Pharmaceuticals by ICP-MS
Validation of quantitative method for determination of elemental impurities in pharmaceutical products following USP 232/233 on ICPMS-2030